| Methods |
2‐week placebo run‐in; inclusion criteria= supine and standing DBP 95‐120 mm Hg after run‐in; 4‐week double‐blind treatment |
| Participants |
Ramipril 2.5 mg: n=28(12 males,16 females); median age=54 years; baseline SBP=162.0 mm Hg, DBP=101.1 mm Hg;
Ramipril 5 mg: n=29(11 males,18 females); median age=53 years; baseline SBP=166.8 mm Hg, DBP=103.2 mm Hg;
Placebo: n=27(15 males,12 females); median age=52 years; baseline SBP=166.6 mm Hg, DBP=101.5 mm Hg |
| Interventions |
Ramipril 2.5 mg once daily;
Ramipril 5 mg once daily;
Placebo;
administered between 6 AM and 8 AM |
| Outcomes |
Mean change from baseline in trough standing SBP/DBP using mercury sphygmomanometer;
Mean change from baseline in trough supine SBP/DBP using mercury sphygmomanometer;
WDAE |
| Notes |
BP change and SEM of change reported, endpoint BP and SD not reported; calculated SD of change from N and change SE; BP data from Tables III and IV, p. 112D; Jadad score=3; funding source= Hoechst AG |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
